influenza
caus
influenza
viru
import
human
respiratori
infecti
diseas
caus
death
worldwid
everi
year
recent
year
drugresist
strain
new
type
influenza
continu
emerg
caus
influenza
epidem
constant
seriou
issu
vaccin
effect
way
control
influenza
howev
influenza
vaccin
current
avail
subtypespecif
fail
protect
patient
type
antigen
variant
viru
furthermor
influenza
viru
undergo
frequent
unpredict
mutat
necessit
annual
vaccin
updat
limit
applic
vaccin
also
wast
manpow
materi
resourc
thu
develop
univers
vaccin
provid
broad
protect
control
season
influenza
epidem
occasion
outbreak
pandem
essenti
influenza
viru
protein
integr
membran
protein
express
viral
surfac
low
quantiti
abundantli
present
surfac
infect
cell
express
pattern
play
import
role
viral
replic
protein
consist
ntermin
extracellular
region
transmembran
region
ctermin
cytoplasm
tail
region
compos
amino
acid
highli
conserv
among
differ
influenza
subtyp
thu
region
may
good
candid
epitop
prepar
univers
vaccin
howev
natur
state
viral
low
immunogen
abund
improv
immunogen
previou
studi
use
multimer
form
creat
fuse
highli
immunogen
carrier
appli
conjunct
adjuv
main
type
vaccin
includ
peptid
vaccin
recombin
protein
vaccin
viruslik
particl
current
sever
univers
vaccin
enter
clinic
trial
howev
problem
surfac
clinic
trial
prevent
commerci
vaccin
promin
problem
includ
unsatisfactori
immun
efficaci
certain
side
effect
problem
may
due
vaccin
contain
multipl
ingredi
moreov
type
vaccin
rel
high
cost
product
complex
manufactur
techniqu
limit
develop
therefor
research
vaccin
necessari
among
variou
type
vaccin
dna
vaccin
particularli
attract
simplic
eas
product
lack
antivector
immun
respons
though
develop
novel
crossprotect
influenza
vaccin
base
dna
promis
strategi
enhanc
immunogen
vaccin
strategi
success
thu
research
necessari
studi
use
combin
strategi
improv
immunogen
dna
vaccin
first
increas
epitop
densiti
use
combin
gene
construct
contain
three
gene
tandem
next
gene
codon
optim
perform
increas
express
final
coupl
secretori
signal
sequenc
tissu
plasminogen
activ
tpa
form
improv
protein
secret
enhanc
dna
vaccin
test
mice
determin
protect
effect
influenza
viru
knowledg
first
time
optim
dna
vaccin
particular
modif
test
vivo
homolog
heterolog
virus
three
sequenti
repeat
gene
conjug
linker
join
cterminu
tpa
without
tpa
figur
detect
express
vitro
transfect
cell
western
blot
perform
shown
figur
b
c
highli
express
cell
lysat
supernat
fact
protein
express
undetect
supernat
cell
transfect
data
indic
addit
tpa
signal
sequenc
greatli
enhanc
express
secret
protein
cell
balbc
mice
vaccin
differ
dna
construct
figur
show
scheme
follow
experi
level
antibodi
determin
enzymelink
immunosorb
assay
elisa
use
synthes
peptid
antigen
result
show
antibodi
present
immun
group
week
initi
immun
figur
furthermor
antibodi
titer
increas
follow
immun
group
level
higher
group
immun
observ
group
figur
g
notabl
antibodi
detect
immun
group
evalu
tcellrel
immun
effect
specif
immun
respons
test
titer
serum
sampl
high
level
antibodi
induc
immun
group
suggest
induc
immun
respons
figur
b
e
h
moreov
titer
similar
indic
induc
balanc
immun
respons
determin
whether
antibodi
produc
follow
dna
vaccin
recogn
nativ
protein
perform
wholecel
elisa
assay
result
show
serum
mice
immun
specif
bind
mdck
cell
indic
antibodi
induc
immun
recogn
protein
surfac
cell
infect
influenza
viru
figur
secret
spleen
cell
known
reflect
cellular
immun
respons
immun
shown
figur
c
number
spot
produc
two
immun
significantli
higher
control
group
p
number
spot
also
gradual
increas
immun
group
figur
f
result
confirm
induct
cell
respons
follow
immun
control
group
also
sever
nonspecif
spot
spot
number
cell
determin
protect
effect
vaccin
mice
infect
lethal
mouseadapt
viru
shown
figur
g
dna
immun
twice
three
time
surviv
rate
mice
viral
challeng
respect
group
respect
thu
surviv
rate
group
better
group
number
immun
particularli
signific
singl
immun
p
control
group
mice
die
within
day
figur
g
result
indic
optim
dna
vaccin
significantli
increas
surviv
rate
mice
infect
homolog
influenza
viru
lung
mice
control
group
high
titer
viru
lung
viru
titer
immun
mice
significantli
lower
control
group
p
addit
number
immun
increas
lung
viral
titer
dna
vaccin
group
gradual
decreas
moreov
number
immun
lung
viral
titer
lower
group
group
figur
b
e
h
also
evalu
weight
loss
viral
challeng
notabl
weight
loss
rate
immun
group
lower
control
group
differ
signific
p
surviv
mice
dna
vaccin
group
recov
slight
loss
bodi
weight
wherea
mice
control
group
die
within
day
postinfect
bodi
weight
loss
figur
c
f
determin
potenti
univers
effect
dna
vaccin
heterolog
virus
mice
infect
avian
origin
mouseadapt
virus
shown
figur
g
found
protect
rate
immun
heterolog
viral
infect
respect
howev
immunizationmedi
protect
signific
infect
group
compar
viral
challeng
control
group
immun
empti
p
differ
immun
group
respect
control
group
signific
similarli
lung
viral
titer
challeng
mice
immun
significantli
lower
control
immun
group
p
differ
challeng
group
immun
compar
respect
control
group
signific
figur
b
e
h
weight
loss
rate
immun
group
also
lower
respect
control
group
inde
surviv
mice
immun
group
began
recov
day
postvir
challeng
figur
c
f
mice
control
immun
group
die
within
day
challeng
bodi
weight
loss
result
demonstr
vaccin
protect
mice
lethal
infect
heterolog
avian
influenza
strain
especi
viru
passiv
immun
also
perform
examin
protect
efficaci
immun
serum
nake
control
vaccin
mice
mice
inject
serum
contain
antibodi
present
clinic
symptom
eg
ruffl
hair
flock
togeth
challeng
none
die
figur
contrast
mice
inject
control
serum
die
within
day
challeng
addit
mice
inject
antibodi
also
show
less
weight
loss
control
group
figur
b
result
suggest
vaccinationmedi
protect
like
provid
circul
antibodi
better
understand
relationship
protect
effici
humor
cellular
immun
respons
correl
coeffici
calcul
respect
humor
immun
respons
surviv
percentag
induc
immun
highli
relat
total
igg
antibodi
level
figur
moreov
surviv
percentag
also
markedli
relat
cellular
immun
respons
figur
thu
protect
efficaci
immun
appear
relat
humor
cellular
immun
respons
present
convent
influenza
vaccin
must
evalu
almost
everi
year
follow
antigen
drift
shift
target
viru
mismatch
circul
strain
influenza
viru
vaccin
strain
may
result
excess
influenzarel
morbid
mortal
make
necessari
develop
univers
vaccin
base
conserv
epitop
studi
creat
novel
dna
vaccin
induc
signific
humor
cellular
immun
respons
reduc
lung
viru
titer
weight
loss
rate
vaccin
provid
better
protect
homolog
virus
also
good
crossprotect
effect
heterolog
virus
knowledg
first
time
optim
dna
vaccin
particular
modif
test
vivo
homolog
heterolog
virus
known
low
immunogen
previou
studi
indic
multipl
tandem
copi
vaccin
construct
elicit
higher
igg
titer
construct
contain
singl
copi
present
studi
creat
appear
induc
higher
product
antibodi
singlecopi
vaccin
consist
previou
research
result
also
report
secretori
antigen
induc
stronger
immun
respons
cellassoci
counterpart
tpa
signal
peptid
locat
endoplasm
reticulum
commonli
use
promot
secret
foreign
protein
therefor
coupl
tpa
increas
protein
express
secret
inde
result
indic
vaccin
induc
higher
express
secret
protein
also
induc
greater
humor
cellular
immun
respons
figur
moreov
challeng
homolog
viru
achiev
complet
protect
two
immun
fail
achiev
complet
protect
even
three
immun
taken
togeth
result
demonstr
increas
express
secret
protein
enhanc
immun
effect
also
highlight
effect
particular
modif
use
studi
mechan
underli
observ
vaccinationmedi
increas
immun
protect
complet
clear
present
howev
report
also
shown
antibodi
play
import
role
protect
immun
inde
antibodi
titer
close
correl
dosedepend
disrupt
viral
life
cycl
death
infect
cell
via
antibodi
depend
cellmedi
cytotox
adcc
present
studi
high
antibodi
titer
induc
immun
group
demonstr
increas
protect
challeng
homolog
viru
addit
mice
antibodymedi
passiv
immun
also
shown
complet
protect
challeng
indic
antibodi
play
import
role
protect
immun
also
observ
lymphocyt
spleen
vaccin
anim
level
found
significantli
correl
protect
notabl
vaccin
induc
higher
tcell
respons
like
relat
abil
secret
protein
affect
cell
type
crossprotect
experi
dna
immun
mice
vaccin
also
appear
effect
heterolog
virus
differ
crossprotect
rate
respect
like
due
differ
sequenc
heterolog
virus
viru
tabl
sequenc
differ
four
six
seven
residu
respect
differ
affect
antibodi
bind
heterolog
protein
result
failur
vaccin
effect
clear
viru
inde
serum
igg
antibodi
mice
vaccin
appear
recogn
three
virus
express
infect
mdck
cell
bind
weakli
compar
mdck
cell
data
shown
conclus
describ
potenti
univers
influenza
vaccin
provid
protect
homo
heterosubtyp
influenza
mice
immun
without
adjuv
induc
high
level
antibodi
product
humoralcellular
immun
respons
protect
balbc
mice
lethal
infect
homo
heterosubtyp
virus
combin
vaccin
strategi
offer
promis
prospect
vaccin
develop
anim
studi
carri
strict
complianc
guidelin
care
use
laboratori
anim
peopl
republ
china
protocol
use
studi
approv
committe
ethic
anim
experi
wuhan
institut
virolog
chines
academi
scienc
procedur
perform
pentobarbit
sodium
anesthesia
effort
made
minim
anim
suffer
influenza
virus
use
mouseadapt
influenza
viru
influenza
viru
aenvironmentdongt
influenza
viru
influenza
virus
passag
adapt
mous
studi
describ
previou
studi
prepar
virus
frozen
use
notabl
virus
use
biosafeti
level
contain
facil
wuhan
institut
virolog
chines
academi
scienc
specificpathogenfre
femal
balbc
mice
week
old
obtain
center
diseas
control
prevent
hubei
provinc
china
anim
bred
anim
resourc
center
wuhan
institut
virolog
chines
academi
scienc
mice
maintain
specificpathogenfre
condit
prior
infect
synthes
genscript
co
ltd
sequenc
link
linker
eukaryot
express
vector
invitrogen
carlsbad
ca
usa
use
construct
dna
vaccin
digest
ecori
xhoi
clone
creat
construct
tpa
signal
sequenc
pcr
use
follow
primer
pcr
product
digest
hindiii
ecori
follow
ligat
creat
singlecopi
plasmid
construct
use
similar
method
plasmid
propag
escherichia
coli
bacteria
purifi
use
xtra
machereynagel
gmbh
co
kg
peptid
slltevetpirnewgcrcngssd
synthes
shanghai
sangon
biolog
engin
technolog
servic
co
ltd
puriti
cell
plate
onto
sixwel
plate
approxim
h
plate
cell
transfect
vector
plasmid
use
lipofectamin
invitrogen
carlsbad
ca
usa
accord
manufactur
instruct
cell
supernat
collect
separ
h
transfect
protein
cell
lysat
supernat
separ
use
nonreduc
sdspage
gel
blot
onto
pvdf
membran
membran
immunoblot
influenza
monoclon
abcam
uk
vivo
electropor
perform
accord
method
describ
aihara
miyazaki
evalu
capabl
dna
vaccin
protect
homolog
influenza
infect
total
nine
group
balbc
mice
n
mice
per
group
respect
immun
three
group
immun
twice
three
time
respect
three
group
immun
twice
three
time
respect
group
immun
three
time
group
immun
three
time
empti
group
immun
three
time
also
allow
us
examin
effect
immun
time
protect
effect
immun
use
refer
notabl
differ
plasmid
phosphat
buffer
salin
pb
inject
right
quadricep
muscl
mous
inject
pair
electrod
needl
insert
muscl
mm
apart
cover
dna
inject
site
electr
puls
deliv
use
electr
puls
gener
btx
san
diego
ca
two
week
last
immun
mice
anesthet
pentobarbit
sodium
dose
mg
kg
anim
challeng
viral
suspens
contain
time
homolog
viru
intranas
drip
viral
challeng
day
three
mice
taken
group
blood
collect
lung
remov
prepar
lung
homogen
measur
viru
titrat
remain
mice
observ
day
record
surviv
rate
weight
loss
immun
induc
high
titer
homogen
antibodi
product
focus
immun
group
heterolog
viru
challeng
experi
total
mice
divid
six
group
n
mice
per
group
three
group
immun
three
time
interv
three
group
immun
empti
control
two
week
third
immun
immun
group
challeng
nasal
drip
time
influenza
virus
respect
mice
observ
day
viral
challeng
weight
loss
surviv
rate
record
viru
titer
lung
collect
day
postchalleng
test
via
assay
blood
collect
day
immun
serum
isol
antibodi
detect
serum
sampl
store
use
mice
group
n
sacrif
day
viral
challeng
lung
isol
lung
homogen
centrifug
rpm
min
centrifug
supernat
collect
viral
titrat
via
assay
antibodi
test
use
plate
coat
synthet
peptid
well
plate
elisa
describ
previous
identifi
antibodi
isotyp
serum
sampl
dilut
bovin
serum
albuminpb
incub
h
room
temperatur
rt
wash
biotinyl
antimous
igg
southern
biotechnolog
associ
inc
usa
conjug
streptavidinhorseradish
peroxidas
hrp
ad
incub
h
rt
sampl
incub
tmb
substrat
min
reaction
stop
phosphor
acid
endpoint
elisa
titer
express
highest
dilut
yield
optic
densiti
greater
mean
plu
two
time
standard
deviat
similarli
dilut
neg
control
sampl
wholecel
elisa
antibodi
perform
well
plate
use
previous
publish
procedur
modif
brief
madindarbi
canin
kidney
mdck
cell
grown
cultur
plate
minimum
essenti
medium
mem
complet
medium
contain
fetal
bovin
serum
fb
cell
almost
cell
incub
virus
pb
medium
alon
uninfect
control
incub
h
complet
medium
ad
well
plate
incub
h
plate
wash
pb
formalin
rt
min
cell
wash
three
time
pb
block
bsa
h
serial
dilut
test
sera
ad
well
incub
h
incub
cell
wash
incub
hrpconjug
goat
antimous
igg
boster
wuhan
china
h
follow
tmb
horseradish
peroxidas
color
develop
solut
elisa
beyotin
biotechnolog
shanghai
china
min
reaction
stop
addit
moll
measur
micropl
spectrophotomet
data
mean
chang
od
triplic
well
per
sampl
mdck
cell
seed
n
cell
per
well
plate
cultur
h
cell
infect
seri
lung
homogen
supernat
incub
h
supernat
replac
serumfre
dulbecco
modifi
eagl
medium
dmem
contain
cocktail
antibiot
cytopath
effect
infect
mdck
cell
observ
daili
incub
day
viru
titer
assay
supernat
measur
hemagglutin
activ
process
data
use
calcul
reed
muench
splenocyt
isol
mice
elispot
assay
week
final
immun
accord
manufactur
instruct
ucytech
netherland
immunospot
plate
millipor
bedford
coat
rat
antimous
interferon
ifn
monoclon
antibodi
incub
overnight
plate
wash
three
time
steril
pb
block
block
solut
r
next
splenocyt
ad
well
triplic
stimul
splenocyt
peptid
h
biotinyl
antimous
antibodi
ad
well
incub
h
subsequ
dilut
streptavidinhrp
conjug
solut
ad
incub
rt
h
final
plate
treat
aec
substrat
solut
incub
rt
min
dark
reaction
stop
wash
deminer
water
spot
quantifi
elispot
reader
bioread
biosi
germani
prepar
high
titer
serum
balbc
mice
n
immun
vaccin
construct
describ
second
group
mice
n
immun
empti
vector
mice
immun
three
time
interv
two
week
final
immun
mice
kill
mice
group
use
control
blood
sampl
collect
serum
prepar
clot
blood
min
follow
centrifug
total
naiv
mice
immun
tail
vein
inject
pool
serum
mice
immun
anoth
group
naiv
mice
receiv
amount
pool
serum
mice
immun
h
mice
anesthet
challeng
influenza
viru
describ
mortal
morbid
weight
loss
monitor
day
challeng
statist
analys
conduct
oneway
analysi
varianc
bonferroni
posttest
use
spss
window
softwar
ver
spss
inc
chicago
il
usa
unpair
twotail
student
ttest
use
compar
mean
differ
group
pvalu
less
consid
statist
signific
differ
surviv
rate
group
analys
use
method
result
express
mean
standard
deviat
sd
